Determinants of Homologous Recombination Deficiency in Pancreatic Cancer

SIMPLE SUMMARY: A subset of patients with pancreatic cancer demonstrate heightened response rates and prolonged survival to platinum chemotherapy and PARP inhibitors. Deficient homologous recombination (HR), a critical DNA repair program, is a major driver of this susceptibility. Furthermore, the cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wattenberg, Max M., Reiss, Kim A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466888/
https://www.ncbi.nlm.nih.gov/pubmed/34572943
http://dx.doi.org/10.3390/cancers13184716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466888/
https://www.ncbi.nlm.nih.gov/pubmed/34572943
http://dx.doi.org/10.3390/cancers13184716

Ejemplares similares